A Phase 2 interventional study of vobramitamab duocarmazine 2.0 mg (Arm A) and vobramitamab duocarmazine 2.7 mg (Arm B) in Castration-Resistant Prostatic Cancer, Androgen-Independent Prostatic Cancer and Androgen-Insensitive Prostatic Cancer, sponsored by MacroGenics. Terminated at 63 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-09.
Sponsored by MacroGenics · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 51 studies in Prostatic Neoplasms, Castration-Resistant with a site in United States — 18 open to participants now, 24 under way, 3 of them phase 3. Prostatic Neoplasms, Castration-Resistant · United States.
Among the 51 studies in Prostatic Neoplasms, Castration-Resistant with a site in United States, this one is the 11th largest by enrollment of the 43 interventional ones that give a count, is one of 6 that started in 2023, is one of 9 in phase 2, and was the 31st registered.
86 studies on the registry are indexed under Prostatic Neoplasms, Castration-Resistant; 29 are open to participants now.
Browse Prostatic Neoplasms, Castration-Resistant studies →18 of the 51 studies in Prostatic Neoplasms, Castration-Resistant with a site in United States are open now. Recruiting first, the newest first:
Coherus Oncology, Inc. · Sites in United States
Ages 18+ · Men only
Novartis Pharmaceuticals · Sites in United States
Ages 18–100 · Men only
Flare Therapeutics Inc. · Sites in United States
Ages 18+ · Men only
Novartis Pharmaceuticals · Sites in United States
Ages 18–115 · Men only
Novartis Pharmaceuticals · Sites in United States
Ages 18–115 · Men only
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 26 Prostatic Neoplasms, Castration-Resistant studies recruiting now, 22 (85%) set no upper age limit and none (0%) stop at 75 or younger; 1 takes children under 18; none take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
51 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 24 · Phase 2 21 · Phase 3 8 · Phase 4 2
First in 2014; this study’s year is marked. 6 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 192 is above the median of 81 across 63 interventional studies indexed under Prostatic Neoplasms, Castration-Resistant.
Median enrollment 82 across the 43 interventional studies, 1,908 across the 6 observational. Of the 23 that completed or were terminated, 11 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
42 of 51 have an industry lead sponsor. The 10 most frequent:
MacroGenics is the lead sponsor of 42 studies on the registry; 4 are open to participants now.
Of its 17 completed or terminated interventional studies of FDA-regulated products, 11 (65%) have results posted.
MacroGenics has 4 studies filed under Prostatic Neoplasms, Castration-Resistant — fewer than ten, so there is no comparison to draw.
8 of the studies in Prostatic Neoplasms, Castration-Resistant with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07225946Phase 3Janssen Research & Development, LLCA Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer | 2027-11-19 |
| NCT07697989Novartis PharmaceuticalsPluvicto Real-world Investigation in Survival in Metastatic CRPC | 2027-01-31 |
| NCT07677254Novartis PharmaceuticalsA Study of Real-World Characteristics, Treatment Patterns, and Clinical Outcomes in Patients With Metastatic Castration-Resistant Prostate Cancer | 2027-05-31 |
| NCT07677267Novartis PharmaceuticalsA Study of Real-World Characteristics, Treatment Patterns, and Outcomes Among mCRPC Patients Previously Treated With an Androgen Receptor Pathway Inhibitor, Taxane-Based Chemotherapy, and Lutetium-177 Vipivotide Tetraxetan | 2027-05-31 |
| NCT05519449Janux TherapeuticsStudy of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01) | 2027-07 |
Add all 8 to your calendar (.ics) → With an account.
Among the 51 studies in Prostatic Neoplasms, Castration-Resistant with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Study CP-MGC018-03 is an open-label, two-part, Phase 2 study. Part 1 of the study will enroll participants with metastatic castration-resistant prostate cancer (mCRPC) previously treated with one prior androgen receptor axis-targeted therapy (ARAT). ARAT includes abiraterone, enzalutamide, or apalutamide.
Participants may have received up to 1 prior docetaxel-containing regimen, but no other chemotherapy agents.
This part of the study will assess the efficacy and tolerability of vobramitamab duocarmazine (MGC018) in two experimental arms (2.0 mg/kg every 4 weeks [Q4W] and 2.7 mg/kg Q4W) . Approximately 100 participants will be randomized 1:1.
Part 2 of the study will enroll participants with locally advanced or metastatic solid tumors. Participants must have progressive following at least 1 prior line of standard chemotherapy for advanced or metastatic disease. Participants will receive vobramitamab duocarmazine at a dose of 2.7 mg/kg every 4 weeks. Up to 200 participants may be enrolled in Part 2.
In both parts, vobramitamab duocarmazine will be administered intravenously (IV) in clinic on Day 1 of each 4-week cycle. Vobramitamab duocarmazine will be administered until criteria for treatment discontinuation are met. Participants will undergo regular testing for signs of disease progression using computed tomography (CT) scans, magnetic resonance imaging (MRI), bone scans, and prostate-specific antigen (PSA) blood tests. Routine examinations and blood tests will be performed and evaluated by the study doctor.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
MGC018 2.0 mg/kg every 4 weeks
Biological: vobramitamab duocarmazine 2.0 mg (Arm A)
MGC018 2.7 mg/kg every 4 weeks
Biological: vobramitamab duocarmazine 2.7 mg (Arm B)
MGC018 2.7 mg/kg every 4 weeks
Biological: vobramitamab duocarmazine
Patients are administered abiraterone or enzalutamide
Drug: Abiraterone · Drug: Enzalutamide
2.0 mg/kg intravenous (IV) every 4 weeks
Also known as: MGC018
2.7 mg.kg IV every 4 weeks
Also known as: MGC018
2.7 mg.kg IV every 4 weeks
Also known as: MGC018
1000 mg once daily
160 mg daily
Part 1: Six-month Radiographic Progression Free Survival (rPFS) as Determined by the Investigator
The landmark analysis for 6 month rPFS rate will occur when all participants on Part 1 have been on study for at least 6 months.
Time frame: Assessed every 8 weeks for six months. Six month data reported.
Part 2: Objective Response Rate (ORR) Per Investigator Assessment of Response Evaluation Criteria in Solid Tumours (RECIST) 1.1 Criteria
The ORR is defined as the percentage of participants in the response evaluable population who achieve a best overall response of complete response (CR) or partial response (PR), per RECIST version 1.1 criterial CR is defined as disappearance of all target and non-target lesions. PR is defined as at least a 30% decrease from baseline in the sum of diameters of target lesions.
Time frame: Every 8 weeks for the first 24 weeks, then every 12 weeks. Average duration of participation, 10 months.
Part 1: ORR Per PCWG3 Criteria as Determined by the Investigator
To qualify as an objective response, CR and PR require confirmation at least 4 weeks after initial observation of complete response (CR) or partial response (PR). CR + PR = ORR
Time frame: Every 8 weeks for the first 24 weeks, then every 12 weeks. Average duration of participation, 10 months,
Part 1: Median Duration of Response (DoR) Per PCWG3 Criteria as Determined by the Investigator
The DoR will be calculated as the time from the date of initial tumor response (CR or PR) to the date of first documented PD or death from any cause, whichever occurs first.
Time frame: Every 8 weeks for the first 24 weeks, then every 12 weeks. Average duration of participation, 10 months.
Part 1: Mean Best Tumor Size Change Over Time
Time frame: Every 8 weeks for the first 24 weeks, then every 12 weeks. Average duration of participation, 10 months.
Part 1: Prostate-specific Cancer Antigen (PSA) Response Rate Per PCWG3 Criteria
PSA response is defined as a ≥ 50% decline in PSA from baseline with PSA confirmation ≥ 3 weeks after the first documented reduction in PSA of ≥ 50%.
Time frame: Every 4 weeks throughout study participation. Average duration 10 months.
Part 1: Time to PSA Progression Per PCWG3 Criteria
In participants with a decrease in PSA from baseline, PSA progression is defined as a ≥ 25% increase and an absolute increase of ≥ 2 ng/mL above the nadir value, which is confirmed by a consecutive second value obtained ≥ 3 weeks later. In participants with no decrease in PSA from baseline, PSA progression is defined as a ≥ 25% increase and an absolute increase of ≥ 2 ng/mL above the baseline value after 12 weeks. Time to PSA progression is defined as the time from the date of randomization to the first PSA progression.
Time frame: Every 4 weeks throughout study participation. Average duration of participation, 10 months.
Part 1: Duration of PSA Response Per PCWG3 Criteria
Duration of PSA response is defined as the time from the date of first documented PSA response to the earliest date of PSA progression.
Time frame: Every 4 weeks throughout study participation. Average duration of participation, 10 months.
Part 1: Best PSA Percent Change
Time frame: Every 4 weeks throughout study participation. Average duration of participation, 10 months.
Part 1: Time to First Symptomatic Skeletal Event (SSE)
An SSE is defined as any of the following events: new symptomatic pathological fracture, requirement for radiation therapy to relieve bone pain, spinal cord compression, or tumor-related orthopedic surgical intervention. The time to first SSE is defined as the time from the date of randomization to the first occurrence of SSE.
Time frame: Every 4 weeks throughout the study. Average duration of participation, 10 months.
Number of Participants With Adverse Event (AEs), Serious AEs (SAEs), and AEs Leading to Study Treatment Discontinuation.
Time frame: Throughout the study, average duration of participation, 10 months.
Number of Participants Who Develop Anti-drug Antibodies (ADA)
Participant specimens were evaluated for the presence of ADA beginning a baseline and throughout the study. If at any time during the study, the results show evidence of ADA, they were counted as ADA positive. There was no time-to- event analysis nor by visit analysis of the data.
Time frame: Every 4 weeks throughout the study, average duration of participation was 10 months.
Part 2: Median DoR Per Investigator Assessment of RECIST 1.1 Criteria
The DoR will be calculated as the time from the date of initial tumor response (CR or PR) to the date of first documented progressive disease (PD) or death from any cause, whichever occurs first.
Time frame: Every 8 weeks for the first 24 weeks, then every 12 weeks. Average duration of participation, 10 months.
Part 2: Median Progression Free Survival (PFS) Per Investigator Assessment of RECIST 1.1 Criteria
PFS is defined as the time from the date of the first dose to the date of first PD per RECIST 1.1 criteria or death from any cause, whichever occurs first.
Time frame: Every 8 weeks for the first 24 weeks, then every 12 weeks. Average duration of participation, 10 months.
| Milestone | Part 1: MGC018 2.0 mg (Arm A) | Part 1: MGC018 2.7 mg (Arm B) | Part 1: Control Arm | Part 2 |
|---|---|---|---|---|
| Started | 91 | 90 | 7 | 4 |
| Intent-to-treat population | 91 | 90 | 7 | 4 |
| Safety population | 90 | 86 | 3 | 4 |
| Tumor response evaluable population | 59 | 49 | 3 | 4 |
| Prostate-specific antigen (psa) response evaluable population | 83 | 71 | 0 | 0 |
| Anti-drug antibody (ada) evaluable population | 90 | 86 | 0 | 4 |
| Completed | 58 | 56 | 2 | 2 |
| Not completed | 33 | 34 | 5 | 2 |
| Withdrew: Death | 23 | 20 | 0 | 2 |
| Withdrew: Lost to follow-up | 1 | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 9 | 13 | 4 | 0 |
| Withdrew: Elected to receive vobramitamab duocarmazine after protocol amendment 2. | 0 | 0 | 1 | 0 |
The landmark analysis for 6 month rPFS rate will occur when all participants on Part 1 have been on study for at least 6 months.
| proportion of participants | Part 1: MGC018 2.0 mg (Arm A) | Part 1: MGC018 2.7 mg (Arm B) | Part 1: Control Arm | Part 2 |
|---|---|---|---|---|
| Part 1: Six-month Radiographic Progression Free Survival (rPFS) as Determined by the Investigator | 0.69 (0.57 to 0.78) | 0.70 (0.46 to 0.79) | 0.47 (0.021 to NA) | — |
The ORR is defined as the percentage of participants in the response evaluable population who achieve a best overall response of complete response (CR) or partial response (PR), per RECIST version 1.1 criterial CR is defined as disappearance of all target and non-target lesions. PR is defined as at least a 30% decrease from baseline in the sum of diameters of target lesions.
| percentage of participants | Part 2 |
|---|---|
| Part 2: Objective Response Rate (ORR) Per Investigator Assessment of Response Evaluation Criteria in Solid Tumours (RECIST) 1.1 Criteria | 0 |
To qualify as an objective response, CR and PR require confirmation at least 4 weeks after initial observation of complete response (CR) or partial response (PR). CR + PR = ORR
| percentage of participants | Part 1: MGC018 2.0 mg (Arm A) | Part 1: MGC018 2.7 mg (Arm B) | Part 1: Control Arm | Part 2 |
|---|---|---|---|---|
| Part 1: ORR Per PCWG3 Criteria as Determined by the Investigator | 13.6 | 30.6 | 0 | — |
The DoR will be calculated as the time from the date of initial tumor response (CR or PR) to the date of first documented PD or death from any cause, whichever occurs first.
| months | Part 1: MGC018 2.0 mg (Arm A) | Part 1: MGC018 2.7 mg (Arm B) | Part 1: Control Arm | Part 2 |
|---|---|---|---|---|
| Part 1: Median Duration of Response (DoR) Per PCWG3 Criteria as Determined by the Investigator | 9.4 (3.68 to NA) | 9.1 (5.78 to 9.92) | — | — |
| percent change from baseline | Part 1: MGC018 2.0 mg (Arm A) | Part 1: MGC018 2.7 mg (Arm B) | Part 1: Control Arm | Part 2 |
|---|---|---|---|---|
| Part 1: Mean Best Tumor Size Change Over Time | -13.0 ± 59.70 | -29.0 ± 33.92 | -7.44 ± 7.16 | — |
PSA response is defined as a ≥ 50% decline in PSA from baseline with PSA confirmation ≥ 3 weeks after the first documented reduction in PSA of ≥ 50%.
| percent | Part 1: MGC018 2.0 mg (Arm A) | Part 1: MGC018 2.7 mg (Arm B) | Part 1: Control Arm | Part 2 |
|---|---|---|---|---|
| Part 1: Prostate-specific Cancer Antigen (PSA) Response Rate Per PCWG3 Criteria | 45.8 (34.8 to 57.1) | 38.0 (26.8 to 50.3) | — | — |
In participants with a decrease in PSA from baseline, PSA progression is defined as a ≥ 25% increase and an absolute increase of ≥ 2 ng/mL above the nadir value, which is confirmed by a consecutive second value obtained ≥ 3 weeks later. In participants with no decrease in PSA from baseline, PSA progression is defined as a ≥ 25% increase and an absolute increase of ≥ 2 ng/mL above the baseline value after 12 weeks. Time to PSA progression is defined as the time from the date of randomization to the first PSA progression.
| months | Part 1: MGC018 2.0 mg (Arm A) | Part 1: MGC018 2.7 mg (Arm B) | Part 1: Control Arm | Part 2 |
|---|---|---|---|---|
| Part 1: Time to PSA Progression Per PCWG3 Criteria | 5.9 (4.63 to 6.97) | 6.9 (4.83 to NA) | 4.6 (NA to NA) | — |
Duration of PSA response is defined as the time from the date of first documented PSA response to the earliest date of PSA progression.
| months | Part 1: MGC018 2.0 mg (Arm A) | Part 1: MGC018 2.7 mg (Arm B) | Part 1: Control Arm | Part 2 |
|---|---|---|---|---|
| Part 1: Duration of PSA Response Per PCWG3 Criteria | 6.1 (4.63 to NA) | NA (5.13 to NA) | — | — |
| percent change from baseline | Part 1: MGC018 2.0 mg (Arm A) | Part 1: MGC018 2.7 mg (Arm B) | Part 1: Control Arm | Part 2 |
|---|---|---|---|---|
| Part 1: Best PSA Percent Change | -28.7 ± 67.05 | -33.1 ± 70.89 | — | — |
An SSE is defined as any of the following events: new symptomatic pathological fracture, requirement for radiation therapy to relieve bone pain, spinal cord compression, or tumor-related orthopedic surgical intervention. The time to first SSE is defined as the time from the date of randomization to the first occurrence of SSE.
| days | Part 1: MGC018 2.0 mg (Arm A) | Part 1: MGC018 2.7 mg (Arm B) | Part 1: Control Arm | Part 2 |
|---|---|---|---|---|
| Part 1: Time to First Symptomatic Skeletal Event (SSE) | 3.71 ± 1.984 | 2.80 ± 2.142 | — | — |
| Participants | Part 1: MGC018 2.0 mg (Arm A) | Part 1: MGC018 2.7 mg (Arm B) | Part 1: Control Arm | Part 2 |
|---|---|---|---|---|
| Any Adverse Event | 89 | 86 | 3 | 4 |
| Serious Adverse Events | 36 | 44 | 1 | 2 |
| Adverse Events Leading to Discontinuation | 28 | 41 | 0 | 2 |
Participant specimens were evaluated for the presence of ADA beginning a baseline and throughout the study. If at any time during the study, the results show evidence of ADA, they were counted as ADA positive. There was no time-to- event analysis nor by visit analysis of the data.
| participants | Part 1: MGC018 2.0 mg (Arm A) | Part 1: MGC018 2.7 mg (Arm B) | Part 1: Control Arm | Part 2 |
|---|---|---|---|---|
| Positive ADA at baseline | 0 | 0 | — | 0 |
| Positive ADA at any time after dosing. | 22 | 16 | — | 0 |
The DoR will be calculated as the time from the date of initial tumor response (CR or PR) to the date of first documented progressive disease (PD) or death from any cause, whichever occurs first.
No measurements were reported for this outcome.
PFS is defined as the time from the date of the first dose to the date of first PD per RECIST 1.1 criteria or death from any cause, whichever occurs first.
| months | Part 2 |
|---|---|
| Part 2: Median Progression Free Survival (PFS) Per Investigator Assessment of RECIST 1.1 Criteria | NA (NA to NA) |
Collected over Adverse events were collected for each participant from the time of first dose through 28 days after the last dose of study treatment or until the start of another anti-cancer treatment, up to average duration of participation, 10 months months. All-cause mortality was assessed from the time of first dose until death, or participant withdrawal of consent, or the end of the study, whichever was earlier, up to average duration of participation, 10 months.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part 1: MGC018 2.0 mg (Arm A) | 25/90 (27.8%) | 36/90 (40%) | 89/90 (98.9%) |
| Part 1: MGC018 2.7 mg (Arm B) | 21/86 (24.4%) | 44/86 (51.2%) | 86/86 (100%) |
| Part 1: Control Arm | 1/3 (33.3%) | 1/3 (33.3%) | 3/3 (100%) |
| Part 2 | 2/4 (50%) | 2/4 (50%) | 4/4 (100%) |
| Event | Part 1: MGC018 2.0 mg (Arm A) | Part 1: MGC018 2.7 mg (Arm B) | Part 1: Control Arm | Part 2 |
|---|---|---|---|---|
| ConstipationGastrointestinal disorders | 0/90 | 0/86 | 1/3 | 0/4 |
| Acute kidney injuryRenal and urinary disorders | 0/90 | 0/86 | 1/3 | 1/4 |
| Urinary retentionRenal and urinary disorders | 0/90 | 0/86 | 1/3 | 0/4 |
| Abdominal painGastrointestinal disorders | 0/90 | 1/86 | 0/3 | 1/4 |
| AscitesGastrointestinal disorders | 0/90 | 0/86 | 0/3 | 1/4 |
| NauseaGastrointestinal disorders | 0/90 | 0/86 | 0/3 | 1/4 |
| VomitingGastrointestinal disorders | 0/90 | 0/86 | 0/3 | 1/4 |
| FatigueGeneral disorders | 0/90 | 0/86 | 0/3 | 1/4 |
| Decreased appetiteMetabolism and nutrition disorders | 0/90 | 0/86 | 0/3 | 1/4 |
| HyponatraemiaMetabolism and nutrition disorders | 0/90 | 0/86 | 0/3 | 1/4 |
| Event | Part 1: MGC018 2.0 mg (Arm A) | Part 1: MGC018 2.7 mg (Arm B) | Part 1: Control Arm | Part 2 |
|---|---|---|---|---|
| FatigueGeneral disorders | 25/90 | 20/86 | 2/3 | 2/4 |
| Back painMusculoskeletal and connective tissue disorders | 8/90 | 10/86 | 2/3 | 1/4 |
| AstheniaGeneral disorders | 47/90 | 52/86 | 0/3 | 0/4 |
| ConstipationGastrointestinal disorders | 22/90 | 20/86 | 0/3 | 2/4 |
| HeadacheNervous system disorders | 12/90 | 16/86 | 0/3 | 2/4 |
| Oedema peripheralGeneral disorders | 33/90 | 35/86 | 0/3 | 1/4 |
| Decreased appetiteMetabolism and nutrition disorders | 33/90 | 35/86 | 0/3 | 0/4 |
| NauseaGastrointestinal disorders | 32/90 | 26/86 | 1/3 | 0/4 |
| Pleural effusionRespiratory, thoracic and mediastinal disorders | 25/90 | 29/86 | 0/3 | 0/4 |
| AnaemiaBlood and lymphatic system disorders | 19/90 | 23/86 | 1/3 | 1/4 |
| Age, Continuous(years) | Part 1: MGC018 2.0 mg (Arm A) | Part 1: MGC018 2.7 mg (Arm B) | Part 1: Control Arm | Part 2 | Total |
|---|---|---|---|---|---|
| Mean | 70.3 ± 9.03 | 69.1 ± 8.94 | 65.7 ± 10.47 | 51.8 ± 12.97 | 69.2 ± 9.45 |
| Sex/Gender, Customized(Participants) | Part 1: MGC018 2.0 mg (Arm A) | Part 1: MGC018 2.7 mg (Arm B) | Part 1: Control Arm | Part 2 | Total |
|---|---|---|---|---|---|
| Female | 0 | 0 | 0 | 3 | 3 |
| Male | 90 | 90 | 7 | 1 | 188 |
| Undifferentiated | 1 | 0 | 0 | 0 | 1 |
| Ethnicity (NIH/OMB)(Participants) | Part 1: MGC018 2.0 mg (Arm A) | Part 1: MGC018 2.7 mg (Arm B) | Part 1: Control Arm | Part 2 | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 11 | 8 | 0 | 0 | 19 |
| Not Hispanic or Latino | 47 | 50 | 6 | 4 | 107 |
| Unknown or Not Reported | 33 | 32 | 1 | 0 | 66 |
| Race (NIH/OMB)(Participants) | Part 1: MGC018 2.0 mg (Arm A) | Part 1: MGC018 2.7 mg (Arm B) | Part 1: Control Arm | Part 2 | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 3 | 3 | 1 | 1 | 8 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 2 | 4 | 0 | 0 | 6 |
| White | 49 | 46 | 6 | 2 | 103 |
| More than one race | 1 | 0 | 0 | 0 | 1 |
| Unknown or Not Reported | 36 | 37 | 0 | 1 | 74 |
| Region of Enrollment(participants) | Part 1: MGC018 2.0 mg (Arm A) | Part 1: MGC018 2.7 mg (Arm B) | Part 1: Control Arm | Part 2 | Total |
|---|---|---|---|---|---|
| South Korea | 2 | 3 | 1 | 0 | 6 |
| Belgium | 4 | 5 | 0 | 0 | 9 |
| United States | 11 | 10 | 1 | 4 | 26 |
| Poland | 8 | 8 | 0 | 0 | 16 |
| Italy | 3 | 4 | 0 | 0 | 7 |
| United Kingdom | 6 | 4 | 4 | 0 | 14 |
| Australia | 4 | 1 | 1 | 0 | 6 |
| France | 35 | 35 | 0 | 0 | 70 |
| Spain | 18 | 20 | 0 | 0 | 38 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jun 2023 to primary completion in Jul 2024, 12 months.
Results were first posted in Feb 2026, 1 year 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Vobramitamab duocarmazine
Prostatic Neoplasms, Castration-Resistant →